Fundamental Analysis of Odonate Therapeutics - Growth / Value Index


ODTC - Valuation Highlights

Valuation Analysis

   Price to Book Ratio is 0.486 indicating that it is undervalued.
   Book Value in last 3 years is trending down
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -0.537 -0.390 -5.28 %
Price to Book 0.486 0.362 41.81 % 0.797
Price to Sales 0 0 0 %
Enterprise Value to EBITDA Multiple 1.54 0.852 -31.52 %


ODTC - Profitability Highlights

Profitability Analysis

   Steady Growth in EPS for last four quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Piotroski F Score - Very Poor Value of 1.0
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -90.64 -92.81 -34.70 % -19.61
Return On Asset -69.52 -75.26 -27.08 % -13.23
Net Profit Margin 0 0 0 % 0
Operating Profit Margin 0 0 0 % 0
EBITDA Margin 0 0 0 % 0


Highlights
Market Cap21937.50
Enterprise Value-156585.06 K
Price/Book TTM0.486
Outstanding Share14625.00
Float/ Outstanding Share120.12%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score1.00                  
Altman Z Score-4.59                  
Sloan Ratio-0.076
Peter Lynch Fair Value0


ODTC - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Quarterly sales in last 5 years is trending up
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue NA % %
Gross Profit NA % %
EBITDA -101571.00 K 12.98 % 36.61 %
Net Profit -102066.00 K 12.99 % 36.42 %
EPS -2.80 5.02 % NA


ODTC - Stability Highlights

Stability Analysis

   Cash ratio of 5.81
   Altman Z Score of -4.59 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of 0
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.0048 149.02 % 0.0104
Cash Ratio 5.81 -20.24 %
Quick Ratio 0 0 % 3.29
Shareholders Equity 81.09 -5.65 %
Debt to EBITDA -0.0052 -84.90 %


Historical Valuation Ratios of Odonate Therapeutics

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Odonate Therapeutics

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Odonate Therapeutics

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Odonate Therapeutics

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)